Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Matheus Freitas Cardoso de, Azevedo"'
Autor:
Luisa Leite Barros, Gabriela Leite, Walter Morales, Gillian M. Barlow, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, Adérson Omar Mourão Cintra Damião, Mark Pimentel, Alberto Queiroz Farias
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Despite adequate treatment, a subgroup of patients with inflammatory bowel disease (IBD), including Crohn`s disease and ulcerative colitis, have persistent gastrointestinal symptoms that are not always related to mucosal damage. R
Externí odkaz:
https://doaj.org/article/cc4a523605824fefa93ca337d050bbea
Autor:
Camilla de Almeida Martins, Matheus Freitas Cardoso de Azevedo, Alexandre Sousa Carlos, Aderson Omar Mourão Cintra Damião, Carlos Walter Sobrado Junior, Sergio Carlos Nahas, Natália Sousa Freitas Queiroz
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Biological therapies have revolutionized the treatment of patients with inflammatory bowel disease (IBD). Infliximab (IFX) has been shown to be effective in inducing and maintaining remission in patients with Crohn’s disease and ulcerat
Externí odkaz:
https://doaj.org/article/5cfd1ca8e5474ee9832b98f121b984d0
Autor:
Matheus Freitas Cardoso de Azevedo, Luísa Leite Barros, Filipe Fernandes Justus, Jane Oba, Karoline Soares Garcia, Camilla de Almeida Martins, Alexandre de Sousa Carlos, André Zonetti Arruda Leite, Aytan Miranda Sipahi, Natália Sousa Freitas Queiroz, Adérson Omar Mourão Cintra Damião
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background/Aims: Anti-tumor necrosis factor (anti-TNF) drugs have been the mainstay therapy for moderate to severe inflammatory bowel disease (IBD) over the past 25 years. Nevertheless, these drugs are associated with serious opportunistic infections
Externí odkaz:
https://doaj.org/article/e170d93ec28645a19b9a9c3b4109c888
Autor:
Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Natália Sousa Freitas Queiroz, Aderson Omar Mourão Cintra Damião, Matheus Freitas Cardoso de Azevedo, Liliana Andrade Chebli, Erika Ruback Bertges, Antonio José Tiburcio Alves Junior, Orlando Ambrogini Junior, Bianca Loyo Pona Schiavetti da Silva, Marcio Lubini, Mauro Bafutto, Cristina Flores, Eduardo Garcia Vilela, Sandra Felice Boratto, Newton Luiz Tricarico Gasparetti Junior, Flavio Steinwurz, Nayara Salgado Carvalho, Omar Féres, José Joaquim Ribeiro da Rocha
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background The effectiveness of ustekinumab (UST) in the treatment of Crohn’s disease (CD) has been demonstrated in the pivotal Phase 3 UNITI 1 and 2 and IM-UNITI studies in both anti-TNF-naïve and anti-TNF-exposed patients. Given the sel
Externí odkaz:
https://doaj.org/article/1ae676670dde47428b23d064b72c8265
Autor:
Karoline Soares Garcia, Matheus Freitas Cardoso de Azevedo, Alexandre de Sousa Carlos, Luísa Leite Barros, Jane Oba, Carlos Walter Sobrado Junior, Aytan Miranda Sipahi, Olívia Duarte de Castro Alves, Tomás Navarro-Rodriguez, Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Liliana Andrade Chebli, Cristina Flores, Andrea Vieira, Christianne Damasceno Arcelino do Ceará, Natália Sousa Freitas Queiroz, Aderson Omar Mourão Cintra Damião
Publikováno v:
Biomedicines, Vol 11, Iss 6, p 1757 (2023)
Therapeutic drug monitoring (TDM) during induction therapy with anti-tumor necrosis factor drugs has emerged as a strategy to optimize response to these biologics and avoid undesired outcomes related to inadequate drug exposure. This study aimed to d
Externí odkaz:
https://doaj.org/article/a40212136539406fadaf057714be969e
Autor:
Karoline Soares Garcia, Bruna Damásio Moutinho, Matheus Freitas Cardoso de Azevedo, Natalia Sousa Freitas Queiroz, Luciane Reis Milani, Lucas Navarro Sanches, Luisa Leite Barros, Jane Oba, Alexandre de Sousa Carlos, Aderson Omar Mourão Cintra Damião, Aytan Miranda Sipahi
Publikováno v:
Inflammatory Intestinal Diseases, Vol 5, Iss 2, Pp 93-98 (2020)
Introduction: The coronavirus disease 2019 (COVID-19) pandemic has increased concern regarding SARS-CoV-2 infection in inflammatory bowel disease (IBD) patients, especially those on immunosuppressive therapies or with active disease. There are limite
Externí odkaz:
https://doaj.org/article/91d328e52bec4d948faba2f9668fb7d9
Publikováno v:
Gastro Hep Advances, Vol 1, Iss 5, Pp 792-793 (2022)
In view of the increase in the therapeutic arsenal available for the treatment of inflammatory bowel disease in recent years, concerns about safety and side effects of immunosuppressive therapies have been increasingly common in clinical practice. Th
Externí odkaz:
https://doaj.org/article/5f97fd8eb33847f38e92d87cc803aaad
Autor:
Adriana Ribas Andrade, Tania Rubia Flores da Rocha, Carmen Lucia Ortiz-Agostinho, Iêda Nishitokukado, Alexandre Sousa Carlos, Matheus Freitas Cardoso de Azevedo, Claudio Lioshi Hashimoto, Aderson Omar Moura Cintra Damião, Flair José Carrilho, Elbio D’Amico, Aytan Miranda Sipahi, André Zonetti de Arruda Leite
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 13 (2020)
Background: As Crohn’s disease (CD) is associated with a high risk of thromboembolic events (TE), including patients with subclinical inflammation, we aim to evaluate the correlation between the impact of endoscopic activity (EA) in the coagulation
Externí odkaz:
https://doaj.org/article/4fb7f1d831b44287b2c266d1bbb1c2c4
Autor:
Natália Sousa Freitas Queiroz, Luísa Leite Barros, Matheus Freitas Cardoso de Azevedo, Jane Oba, Carlos Walter Sobrado, Alexandre de Sousa Carlos, Luciane Reis Milani, Aytan Miranda Sipahi, Aderson Omar Mourão Cintra Damião
Publikováno v:
Clinics, Vol 75 (2020)
The world is fighting the COVID-19 outbreak and health workers, including inflammatory bowel diseases specialists, have been challenged to address the specific clinical issues of their patients. We hereby summarize the current literature in the manag
Externí odkaz:
https://doaj.org/article/fdf3284515e24a54aa244901595de1ec
Autor:
Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Natália Sousa Freitas Queiroz, Aderson Omar Mourão Cintra Damião, Matheus Freitas Cardoso de Azevedo, Liliana Andrade Chebli, Erika Ruback Bertges, Antonio José Tiburcio Alves Junior, Orlando Ambrogini Junior, Bianca Loyo Pona Schiavetti da Silva, Marcio Lubini, Mauro Bafutto, Cristina Flores, Eduardo Garcia Vilela, Sandra Felice Boratto, Newton Luiz Tricarico Gasparetti Junior, Flavio Steinwurz, Nayara Salgado Carvalho, Omar Féres, José Joaquim Ribeiro da Rocha
Publikováno v:
BMC gastroenterology. 22(1)
Background The effectiveness of ustekinumab (UST) in the treatment of Crohn’s disease (CD) has been demonstrated in the pivotal Phase 3 UNITI 1 and 2 and IM-UNITI studies in both anti-TNF-naïve and anti-TNF-exposed patients. Given the selective na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1dd2f56d455c2220c89d588d1ef376b
https://pubmed.ncbi.nlm.nih.gov/35448949
https://pubmed.ncbi.nlm.nih.gov/35448949